Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 2Thoracic 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 410Lung Neoplasms 261Small Cell Lung Carcinoma 75Colorectal Neoplasms 71Breast Neoplasms 52Ovarian Neoplasms 48Neoplasms 48Melanoma 48Pancreatic Neoplasms 45Neoplasm Metastasis 38Squamous Cell Carcinoma of Head and Neck 36Stomach Neoplasms 31Prostatic Neoplasms 28Head and Neck Neoplasms 27Esophageal Neoplasms 26Carcinoma, Renal Cell 26Endometrial Neoplasms 25Colonic Neoplasms 24Triple Negative Breast Neoplasms 23Uterine Cervical Neoplasms 22Urinary Bladder Neoplasms 21Carcinoma, Hepatocellular 21Mesothelioma, Malignant 14Mesothelioma 14Sarcoma 13Parkinson Disease 4, Autosomal Dominant Lewy Body 13Lung Diseases 13Liver Neoplasms 13Carcinoma, Transitional Cell 13Thyroid Neoplasms 12

Interventions

tislelizumab 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Solid Tumors × Thoracic × 30 days × Clear all
NCT06585488 2026-06-03

A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification

BeOne Medicines

Phase 1 Terminated
47 enrolled
GastrointestinalOther solid neoplasmThoracic

Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡